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Edited by Horst FeldmannAbstract The sleeping beauty (SB) transposon system has po-
tential utility in gene transfer applications but lacks speciﬁcity
for genomic integration and exhibits overproduction inhibition
which limits in vivo activity. Targeting transposition may be pos-
sible by coupling a speciﬁc DNA binding domain to the SB trans-
posase, but it is not known if this strategy will preserve or disrupt
activity of the system. We engineered and tested chimeric SB
transposases with two diﬀerent human zinc ﬁnger DNA binding
domain elements, Sp1 and zinc ﬁnger 202 (ZNF202). Addition
of Sp1 to the C-terminus abolished transposase activity whereas
N-terminal addition of either Sp1 or ZNF202 did not. Transpo-
sition activity exhibited by N-terminal chimeras was increased to
levels similar to native SB through the use of a hyperactive
transposase (SB12) and activating transposon mutations.
Importantly, addition of DNA binding domains to the transpos-
ase N-terminus resulted in attenuation of overproduction
inhibition, a major limitation of this system. These ﬁndings
suggest that SB transposase chimeras may have speciﬁc
advantages over the native enzyme.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Transfer of DNA to a living cell has many potential applica-
tions and transposon-based systems represent promising new
tools for establishment of persistent transgene expression.
The sleeping beauty (SB) transposon system belonging to the
Tc1/mariner superfamily of transposable elements has been
demonstrated to be useful for gene transfer in animals [1–7].
SB has the highest transpositional activity of any transposon
system studied thus far in vertebrates and has potential utility
in human gene therapy [8]. The intrinsic activity of the SB sys-
tem has been enhanced through a variety of measures includ-
ing the creation of hyperactive SB transposases [9,10], andAbbreviations: SB, sleeping beauty; pT, SB transposon; HA, hemag-
glutinin; HEK293, human embryonic kidney cells; PCR, polymerase
chain reaction; ZNF202, zinc ﬁnger 202; IR, inverted repeat
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doi:10.1016/j.febslet.2005.10.004by engineering transposons with identical 3 0 and 5 0 inverted re-
peats (IR) [10].
There are two major limitations of the SB system that com-
promise its potential usefulness in gene therapy applications:
the tendency for random genomic integration at TA dinucleo-
tide elements [5,10–13], and overproduction inhibition [5,9].
Hypothetically, random integration might be overcome by fus-
ing SB transposase to a speciﬁc DNA binding domain thereby
promoting genomic integration in a site-selective manner [14].
A recent report demonstrated targeted integration in a plas-
mid-based assay using the bacterial transposase IS30 fused
to a DNA binding domain [15].
Overproduction inhibition occurs with members of the Tc1/
mariner transposon family and results in lower transpositional
activity at higher transposase concentrations [16,17]. This
phenomenon has been observed for both native and hyperac-
tive SB enzymes [5,9], but the mechanism of overproduction
inhibition is unknown. Overproduction inhibition occurs
in vivo and transposition eﬃcacy in mice has been demon-
strated to vary depending upon promoter strength with higher
SB transposase expression leading to lower levels of transpo-
sition [18,19]. This phenomenon creates suboptimal condi-
tions for gene transfer and application of SB transposases
to gene therapy.
To address these limitations of the SB system, we engineered
and tested transposase/DNA binding domain chimeras to
determine their activity level and functional properties. These
experiments demonstrated that N-terminal fusion of speciﬁc
zinc ﬁnger domains to the SB transposase preserved activity
and greatly attenuated overproduction inhibition. Our study
provides a potential strategy for improving the SB system as
a vehicle for transgene delivery to human cells.2. Materials and methods
2.1. Generation of SB transposase chimeras with Sp1 DNA binding
domain
Plasmids pCMV–SB, pCMV–mSB, and pT-Nori (herein referred to
as pT) were provided byMarkKay, pCMV–SB12 was provided by Zol-
tan Ivics, and pPacSp1 was provided by Michael Waterman. Recombi-
nant polymerase chain reaction (PCR) was used to add DNA binding
domain of Sp1 (amino acids 534–623) to either the N-terminus or C-ter-
minus of SB transposases (all primer sequences are available upon re-
quest). Construction of C-terminal DNA binding domain chimeras
was accomplished by removal of the natural transposase stop codon,
addition of a tripeptide (Gly-Thr-Gly) spacer (containing a uniqueKpnI
site) followed by the DNA binding domain, hemagglutinin (HA) tagblished by Elsevier B.V. All rights reserved.
Fig. 1. Schematic representations of recombinant chimeric SB trans-
posases. Each horizontal bar represents a speciﬁc recombinant protein
annotated with the following abbreviations: mSB (DDDE), catalyti-
cally inactive SB transposase; SB12, hyperactive SB transposase; Sp1,
Sp1 DNA binding domain fused to either the N-terminus (Sp1SB) or
C-terminus (SBSp1) of SB transposase; Sp1SB denotes a construct
with a minimal peptide linker sequence of Gy-Thr-Gly between protein
domains; Sp1-SB denotes chimera constructed using linker 1 as
described in Section 2; Sp1–SB, denotes chimera constructed with
linker 2; * denotes absence of additional nuclear localization signal;
NLS, denotes additional N-terminal nuclear localization signal derived
from the SV40 large T antigen; HA, epitope tag; ZNF202, ZNF202
DNA binding domain.
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struction of N-terminal chimeras included a SV40 T-antigen nuclear
localization signal (MPKKKRKV) followed by HA, the corresponding
DNA binding domain, tripeptide spacer, and the transposase cDNA.
Recombinant PCR products were restriction digested and subcloned
into either pCMV–SB or pCMV–Sp1–SB. To modify the distance be-
tween DNA binding domain and transposase, constructs were digested
with KpnI, dephosphorylated, and ligated to one of two possible dou-
ble-stranded linkers encoding 19 (linker 1: GTGSGGSGGSGGSGTS
GTG) or 18 (linker 2: GTTVDRSSDPTSQTSGTG) amino acid resi-
dues.HighﬁdelityDNApolymerase (ExpandTaq, RocheDiagnostics,
Indianapolis, IN)was used for all PCRs to reduce polymerase errors. All
DNA constructs were veriﬁed by automated DNA sequencing.
2.2. Generation of ZNF202–SB12 transposase chimera
Zinc ﬁngers 3-8 of the human zinc ﬁnger 202 (ZNF202) were cloned
from human genomic DNA and fused to the N-terminus of SB and
SB12 transposases by recombinant PCR as described above for Sp1
chimeras. Final PCR products were subcloned into pCMV–Sp1–
SB12 and the ﬁnal construct was veriﬁed by DNA sequencing.
2.3. Generation of the hyperactive pT3 transposon
Recombinant PCR was used to amplify the left IR/DR structure
from pT as described previously by Yant et al. [10] except that one pri-
mer diﬀered at two nucleotides (see underlined bases: GCGGATCCC-
CTTGAAATACATCCACAGG).
2.4. Western blot analysis of recombinant SB transposase enzymes
Human embryonic kidney (HEK293) cells at 30–50% conﬂuence in a
60 mm dish were transiently transfected with FuGENE-6 (Roche
Diagnostics) and 3 lg of SB transposase plasmid unless otherwise indi-
cated. Three days after transfection, cells were lysed in RIPA lysis buf-
fer (150 mM NaCl, 50 mM Tris, pH 7.5, 1% IPEGAL, 0.5%
deoxycholate, 0.1% SDS) containing a protease inhibitor cocktail
(Roche). Protein concentrations determined by Bradford assay were
used to normalize samples and equivalent protein amounts were sub-
jected to 10% SDS–PAGE. Gels were transferred to nitrocellulose,
then probed with a rat anti-HA antibody (Amersham, Piscataway,
NJ) followed by incubation with a secondary anti-rat horseradish per-
oxidase conjugated antibody (Amersham). Epitope tagged proteins
were detected by enhanced chemiluminescence detection.
2.5. Transposon excision assay
HEK293 cells at 30–50% conﬂuence in a 60 mm dish were transiently
transfected with FuGENE-6 and plasmids containing the transposase
(200 ng) and the transposon DNA segment (2 lg). Three days after
transfection, plasmid DNA was isolated from cells using QiaPrep spin
columns (Qiagen Corporation, Valencia, CA) using the manufacturers
protocol. Isolated plasmid DNA was then used as a template for
nested PCR designed to amplify a 585 bp product from transposon
plasmids which had undergone excision and repair as opposed to the
intact 3.5 kb transposon segment. The PCR product from the ﬁrst
round was diluted 1:50 with water and 5 lL of this was used for the
second round of PCR. Isolated plasmid DNA was also used for
PCR ampliﬁcation of the ampicillin resistance gene to normalize for
the amount of template in each reaction.
2.6. Transposition assay
Transposition events were quantiﬁed in cultured human cells by
transposon-mediated insertion of an antibiotic resistance cassette
[1]. For our experiments, we used a SB transposon (pT or pT3) that
contains a neomycin resistance cassette ﬂanked by IR elements.
Integration of neomycin resistance allowed selection of transposition
events with the aminoglycoside antibiotic G418. HEK 293 cells at
30–50% conﬂuence in a 60 mm dish were transiently transfected with
both transposase and transposon plasmids using FuGene-6. Two
days after transfection, cells were split to varying densities and
placed in media containing 800 lg/mL G418 for selection. After 2
weeks of selection, colonies of cells were ﬁxed, stained with methy-
lene blue and counted [1]. For assessment of overproduction inhibi-
tion, the same assay protocol was used except that each transfection
contained the same total amount of plasmid DNA (empty pIRESp-
uro3 vector was used to supplement transfections when necessary to
maintain DNA quantity).3. Results
3.1. Activity of chimeric SB transposases
We created a series of chimeric recombinant SB transposase
enzymes by fusion of a DNA binding domain to either the N-
or C-terminus of the protein (Fig. 1). Initially, we selected the
zinc ﬁnger DNA binding domain Sp1 [20], a ubiquitous zinc-
ﬁnger transcription factor, as the chimeric partner. Transposi-
tional activity was then tested in HEK293 cells. Addition of
the Sp1 DNA binding domain to the SB C-terminus (SBSp1)
abolished transposase activity. Activity was not restored by
addition of a longer peptide linker sequence between the Sp1
domain and the transposase sequence, the addition of hyperac-
tive mutations to the transposase (SB12) or by reacting the en-
zyme with a hyperactive transposon (pT3) (Fig. 2A). These
experiments demonstrated that the SB transposase appears
not to be amenable to C-terminal addition of protein frag-
ments. This conclusion is supported by experiments that dem-
onstrated abolished SB activity after C-terminal addition of
other DNA binding domains or short peptide sequences (data
not shown). Western analysis revealed expression of both C-
terminal and N-terminal chimeric transposases indicating that
lack of activity with C-terminal fusion of Sp1 was not due to
lack of protein synthesis (Fig. 2C).
By contrast to C-terminal fusions, a chimeric SB transposase
having the Sp1 DNA binding domain added to the N-terminus
(Sp1SB) retained 17 ± 6% of native enzyme activity. The level
of activity observed in the presence of the native transposon IR
elements (pT) was not increased by adding an additional nucle-
ar localization signal (PKKKRKV) to the N-terminus shown
previously to enhance nuclear import of other proteins [21]
or by addition of a longer peptide linker sequence separating
the Sp1 and transposase protein elements. However, the addi-
tion of activating mutations within the transposase (SB12) was
able to increase activity which could be increased further when
used in combination with a hyperactive transposon (pT3) to
85 ± 15% of native SB (Fig. 2A). This level of activity ap-
Fig. 2. Activity of chimeric SB transposases. (A) Transposition assays.
HEK293 cells were transfected with a transposon containing a
neomycin resistance cassette and the recombinant chimeric SB
transposase as indicated in the ﬁgure. Transposition activity was
quantiﬁed by counting colonies after 2 weeks of selection under G418.
Abbreviations are as follows: pT, native transposon; pT3, hyperactive
transposon as described in the text. Data shown are mean values with
S.D. (N = 3–6). (B) Representative excision assay performed with
either native (pT) or hyperactive (pT3) transposons (N = 4). (C)
Immunoblot analysis of expressed recombinant HA-tagged transpos-
ases in HEK293 cells. Molecular weight standards are indicated to the
right of the panel.
Fig. 3. Analysis of ZNF202–SB12 chimeric transposase. (A) Trans-
position assays with ZNF202–SB12 in the presence of pT3 in HEK293
cells (N = 3). (B) Representative excision assay performed in the
presence of pT3 transposon (N = 3). (C) Immunoblot analysis of the
recombinant chimeric transposase expressed in HEK293 cells.
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experiments comparing two linkers of diﬀering amino acid se-
quence shown previously to be eﬀective in chimeric recombin-
ases [22].
We further evaluated the activity of our chimeric transpos-
ases by evaluating for excision of the transposon element from
plasmid DNA in human cells. We co-transfected HEK293 cells
with plasmids encoding the transposase and the transposon.
Three days post transfection, cells were lysed and plasmid
DNA was recovered. Recovered plasmid DNA was then used
as a template for a PCR designed to amplify from plasmids
that have undergone excision and repair. In this case, excision
results in a 585 bp product compared to the non-excised 3 kb
transposon (Fig. 2B). Excision assay analysis revealed that
correct excision was occurring with our N-terminal
Sp1–SB12 chimeric transposase.To determine if a diﬀerent zinc ﬁnger DNA binding domain
could achieve similar results, we engineered another recombi-
nant chimeric transposase by addition of the DNA binding do-
main of ZNF202 to the N-terminus of SB12 (Fig. 3A). Zinc
ﬁngers 3-8 of the ZNF202 protein have been puriﬁed as a glu-
tathione S-transferase fusion protein and demonstrated to
interact with ZNF202 target binding sites in electrophoretic
mobility shift assays [23]. Therefore, we added zinc ﬁngers 3-
8 of ZNF202 to the N-terminus of the SB12 transposase. Anal-
ysis of the activity of the chimeric ZNF202–SB12 transposase
revealed expression and activity in both excision and transpo-
sition assays in HEK293 cells (Fig. 3B–D).
3.2. Chimeric SB transposases exhibit attenuated overproduction
inhibition
Amajor limitation of the SB transposon system, and its abil-
ity to facilitate gene transfer in vitro and in vivo, is termed
overproduction inhibition [5]. Overproduction inhibition is de-
Fig. 4. Overproduction inhibition assays. HEK293 cells were transfected with transposase plasmid DNA and either 200 ng (A) or 2 lg (B) of pT3
transposon DNA, and then analyzed for overproduction inhibition (N = 3). Empty pIRESpuro3 vector was used to supplement transfections when
necessary to maintain a ﬁxed amount of DNA. (C) Western blot (N = 3) of chimeric transposase expression at the varying amounts of DNA used to
test for overproduction inhibition. Each lane was normalized to contain 15 lg total protein lysate using Bradford analysis. (D) Transposition events
using the optimal amount of transposase DNA. In order to compare the maximal activity among transposase constructs, the maximal transpositional
activities of each construct were compared to each other (N = 3). Data are shown as mean values with S.D.
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sion level of transposase. Because of this phenomenon, the le-
vel of promoter activity driving transposase expression has
been demonstrated to aﬀect the success of SB mediated trans-
position of transgenes in animals [19]. High levels of transpos-
ase expression are detrimental to transposition eﬃcacy.
We evaluated overproduction inhibition for native and engi-
neered SB transposases expressed in HEK293 cells. Both SB
and SB12 exhibit overproduction inhibition with less transposi-
tion activity in cells transfected with greater amounts of trans-
posase DNA (Fig. 4A and B). However, both the Sp1–SB12
and ZNF202–SB12 chimeric transposases did not exhibit over-
production inhibition (Fig. 4A and B). This was evaluated in the
context of transfecting a 10-fold range, either 200 ng (Fig. 4A)
or 2 lg (Fig. 4B), of pT3 transposon DNA. Western blot anal-
ysis conﬁrmed that transposase expression was proportional to
the amount of DNA used for transfections (Fig. 4C). Addition-
ally, transfecting a higher amount of chimeric transposase
DNA permitted transposition activity nearly equivalent to that
of native SB (Fig. 4D). These ﬁndings support the conclusion
that N-terminal fusion of a DNA binding domain to SB trans-
posases attenuates overproduction inhibition.4. Discussion
The SB transposon system has been the focus of several
studies seeking a non-viral approach to long-term transgene
expression in mammalian cells. Among transposons, SB has
the highest known activity in vertebrates, but lacks integration
site speciﬁcity and exhibits overproduction inhibition, two lim-itations that must be overcome before the utility of this system
in gene transfer applications can be fully realized.
Our study tests the feasibility of engineering chimeric SB
transposases containing a speciﬁc DNA binding domain, a
proposed strategy for achieving targeted transposition [14].
Despite previous suggestions that modiﬁcation of SB transpos-
ase terminal domains abolishes activity [24], we observed mod-
est activity with N-terminal fusions of zinc ﬁnger DNA
binding domains that could be augmented substantially by
activating mutations in the transposase combined with hyper-
active transposon DNA. Additionally, our experiments with a
ZNF202–SB12 transposase indicate that zinc ﬁnger DNA
binding domains may behave as modular units in this context.
Perhaps synthetic zinc ﬁngers that target unique genomic re-
gions with higher aﬃnity and speciﬁcity may work equally well
to preserve transposase activity.
These proof-of-concept experiments will motivate further
optimization of the system with an eventual goal of testing tar-
geted integration in the human genome. The two DNA binding
domains that we selected for this initial work recognize se-
quence motifs that are quite common in mammalian genomes.
We undertook initial evaluation of integration site preferences
by searching for possible Sp1 binding sites neighboring ran-
domly generated integration events in silico and true integra-
tion events mediated by native SB in HEK293 cells. We
discovered that putative Sp1 binding sites are found at high fre-
quency in randomly selected 2 kb regions of the human genome
as well as within 2 kb of native SB mediated integration events
(data not shown) making it virtually impossible to determine
whether or not targeted integration was occurring. A similar
ﬁnding was made with ZNF202 recognition sequences. Future
M.H. Wilson et al. / FEBS Letters 579 (2005) 6205–6209 6209transposase chimeras with more selective DNA binding ele-
ments should be evaluated.
In characterizing the functional properties of chimeric SB
transposases, we made a serendipitous ﬁnding that these en-
zymes have attenuated overproduction inhibition. This is an
important discovery because reduced overproduction inhibi-
tion may enable higher levels of transposition and greater eﬃ-
ciency of gene transfer. Even though the mechanism of
overproduction inhibition remains elusive, loss of this limita-
tion of the SB transposon system would be beneﬁcial for gene
delivery and thus represents an advantage associated with chi-
meric transposases independent of their potential ability to
direct site-selective integration.
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